Quote | iTeos Therapeutics Inc. (NASDAQ:ITOS)
Last: | $13.17 |
---|---|
Change Percent: | -3.08% |
Open: | $12.73 |
Close: | $13.17 |
High: | $13.42 |
Low: | $12.56 |
Volume: | 478,691 |
Last Trade Date Time: | 03/27/2024 03:00:00 am |
News | iTeos Therapeutics Inc. (NASDAQ:ITOS)
2024-03-06 07:29:55 ET More on iTeos Therapeutics iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones Seeking Alpha’s Quant Rating on iTeos Therapeut...
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointmen...
Message Board Posts | iTeos Therapeutics Inc. (NASDAQ:ITOS)
Subject | By | Source | When |
---|---|---|---|
$14.41 EPS estimate for 3rd quarter posted today | TonyJoe1957 | investorshub | 08/20/2021 11:09:03 AM |
https://seekingalpha.com/article/4449555-iteos-therapeutics-my-calculations-sugg | TonyJoe1957 | investorshub | 08/15/2021 3:00:21 PM |
Wow! No one posting or interested in this stock? | TonyJoe1957 | investorshub | 08/11/2021 3:04:11 PM |
Note the intraday lows for the past 3 | TonyJoe1957 | investorshub | 06/16/2021 7:43:27 PM |
I think we are trading below cash per share. | TonyJoe1957 | investorshub | 06/15/2021 7:23:39 PM |
News, Short Squeeze, Breakout and More Instantly...
iTeos Therapeutics Inc. Company Name:
ITOS Stock Symbol:
NASDAQ Market:
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmace...
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointmen...
- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Completed enrollment of third dose cohort in Phase 1 trial of EOS-984 - Preclinical presentations on role of ENT1 at SITC Sp...